26
Bioengineers are a step closer to making CAR T-cell therapy safer, more precise and easy to control. They developed a system that allows them to select where and when CAR T cells get turned on so that they destroy cancer cells without harming normal cells. The system requires two ‘keys’ — the drug Tamoxifen and blue light — to activate CAR T cells to bind to their targets.